Loading...
XHKG
1931
Market cap1.16bUSD
Dec 05, Last price  
5.60HKD
1D
-0.88%
1Q
-49.46%
IPO
82.41%
Name

Ivd Medical Holding Ltd

Chart & Performance

D1W1MN
XHKG:1931 chart
P/E
31.62
P/S
2.60
EPS
0.16
Div Yield, %
2.22%
Shrs. gr., 5y
5.58%
Rev. gr., 5y
6.27%
Revenues
3.16b
+2.40%
290,441,000338,268,000413,635,0002,332,740,0002,428,210,0002,730,670,0002,748,809,0003,088,387,0003,162,415,000
Net income
260m
+9.35%
56,268,000110,735,000103,440,000275,001,000158,718,000174,541,000209,999,000238,163,000260,420,000
CFO
140m
-52.03%
-23,519,00019,717,0001,959,000340,716,000170,494,000163,108,000249,671,000292,424,000140,287,000
Dividend
Jul 15, 20240.06209 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

IVD Medical Holding Limited, an investment holding company, distributes In vitro diagnostic (IVD) products in Mainland China and internationally. The company operates through three segments: Distribution Business, Maintenance Services, and Self-branded Products Business. It offers IVD analysers, reagents, and other consumables for various IVD testing categories, including hematology and body fluid, immunoassay, clinical chemistry, molecular, microbiology, and point-of-care testing. The company also provides haemostasis products; solution services to the clinical laboratories of hospitals; and maintenance services, such as maintenance and repair, installation, and end customer training services. In addition, it researches, develops, manufactures, and sells IVD analyzers and reagents under the IVD brand. The company offers its products to hospitals and healthcare institutions, logistics providers, and distributors. IVD Medical Holding Limited was founded in 1993 and is headquartered in Shanghai, the People's Republic of China.
IPO date
Jul 12, 2019
Employees
779
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT